McDavid Stilwell Net Worth

The estimated Net Worth of Mc David Stilwell is at least $101 Tausend dollars as of 15 October 2021. Mr Stilwell owns over 3,507 units of Coherus Biosciences Inc stock worth over $42,043 and over the last 3 years he sold CHRS stock worth over $58,918.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Stilwell CHRS stock SEC Form 4 insiders trading

Mr has made over 2 trades of the Coherus Biosciences Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 3,507 units of CHRS stock worth $58,918 on 15 October 2021.

The largest trade he's ever made was buying 3,700 units of Coherus Biosciences Inc stock on 9 June 2021 worth over $49,654. On average, Mr trades about 721 units every 13 days since 2021. As of 15 October 2021 he still owns at least 31,611 units of Coherus Biosciences Inc stock.

You can see the complete history of Mr Stilwell stock trades at the bottom of the page.

Mr. McDavid Stilwell biography

McDavid Stilwell is the Chief Financial Officer at Coherus Biosciences Inc.

How old is Mr Stilwell?

Mr Stilwell is 50, he's been the Chief Financial Officer of Coherus Biosciences Inc since . There are 14 older and 1 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.

What's Mr Stilwell's mailing address?

Mc's mailing address filed with the SEC is COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.

Insiders trading at Coherus Biosciences Inc

Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle und James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.

What does Coherus Biosciences Inc do?

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp

Complete history of Mr Stilwell stock trades at Coherus Biosciences Inc

Coherus Biosciences Inc executives and stock owners

Coherus Biosciences Inc executives and other stock owners filed with the SEC include:

• Dennis Lanfear,
  Chairman of the Board, President, Chief Executive Officer
• Jean-Frederic Viret,
  Chief Financial Officer
• Dennis M. Lanfear,
  Chairman, Pres & CEO
• Vincent Anicetti,
  Chief Operating Officer
• Vladimir Vexler,
  Chief Scientific Officer
• Vladimir Vexler,
  Chief Scientific Officer
• Mats Wahlstrom,
  Lead Independent Director
• V. Bryan Lawlis,
  Independent Director
• Mary Szela,
  Independent Director
• Ali Satvat,
  Independent Director
• James Healy,
  Independent Director
• Samuel Nussbaum,
  Independent Director
• Kimberly Tzoumakas,
  Director
• Thomas Fitzpatrick,
  Chief Legal Officer
• Dr. Barbara K. Finck M.D.,
  Acting Chief Medical Officer
• Richard L. Hameister,
  Chief Quality Officer
• Michael Chen,
  Sr. VP of Commercial Analytics & Trade
• Michael A. Fleming,
  Chief Strategy Officer
• Rebecca Sunshine,
  Exec. VP of HR
• Chris Thompson,
  Exec. VP of Sales
• McDavid Stilwell,
  Chief Financial Officer
• Alan C. Herman,
  Chief Scientific Officer
• August J. Troendle,
  Director
• Christos Richards,
  Director
• Peter K. Watler,
  Chief Technical Officer
• Barbara K Finck,
  Chief Medical Officer
• Rita A Karachun,
  
• Llc Fmr,
  10% owner
• Biosimilar L.P.Kkr Biosimil...,
  
• Eli & Co Lilly Ventures Fun...,
  
• Sankyo Company, Ltd Daiichi,
  
• Georgia Erbez,
  
• Alan C Mendelson,
  Director
• Lee Nisley Newcomer,
  
• Mark Stolper,
  
• Charles W. Newton,
  
• Jill O'donnell Tormey,
  
• Michael Lee Ryan,
  
• Paul Reider,
  Chief Commercial Officer
• Mc David Stilwell,
  Chief Financial Officer
• Bryan J Mc Michael,
  Chief Financial Officer